138 related articles for article (PubMed ID: 7699460)
21. Biology of metaiodobenzylguanidine interactions with human neuroblastoma cells.
Iavarone A; Lasorella A; Servidei T; Riccardi R; Troncone L; Mastrangelo R
J Nucl Biol Med (1991); 1991; 35(4):186-90. PubMed ID: 1823815
[TBL] [Abstract][Full Text] [Related]
22. In vitro pharmacology of metaiodobenzylguanidine uptake, storage and release in human neuroblastoma cells.
Montaldo PG; Carbone R; Lanciotti M; Ponzoni M; Cornaglia-Ferraris P
J Nucl Biol Med (1991); 1991; 35(4):195-8. PubMed ID: 1823817
[TBL] [Abstract][Full Text] [Related]
23. A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.
Vaidyanathan G; Welsh PC; Vitorello KC; Snyder S; Friedman HS; Zalutsky MR
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1362-70. PubMed ID: 15205923
[TBL] [Abstract][Full Text] [Related]
24. No-carrier-added meta-[123I]iodobenzylguanidine: synthesis and preliminary evaluation.
Vaidyanathan G; Zalutsky MR
Nucl Med Biol; 1995 Jan; 22(1):61-4. PubMed ID: 7735171
[TBL] [Abstract][Full Text] [Related]
25. Uptake of mIBG and catecholamines in noradrenaline- and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma- and pheochromocytoma cells.
Bayer M; Kuçi Z; Schömig E; Gründemann D; Dittmann H; Handgretinger R; Bruchelt G
Nucl Med Biol; 2009 Apr; 36(3):287-94. PubMed ID: 19324274
[TBL] [Abstract][Full Text] [Related]
26. No-carrier-added synthesis of meta-[131I]iodobenzylguanidine.
Vaidyanathan G; Zalutsky MR
Appl Radiat Isot; 1993 Mar; 44(3):621-8. PubMed ID: 8472027
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the sodium dependency of uptake of meta-lodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells.
Jaques S; Tobes MC; Sisson JC; Baker JA; Wieland DM
Mol Pharmacol; 1984 Nov; 26(3):539-46. PubMed ID: 6493209
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters.
Glowniak JV; Kilty JE; Amara SG; Hoffman BJ; Turner FE
J Nucl Med; 1993 Jul; 34(7):1140-6. PubMed ID: 8315492
[TBL] [Abstract][Full Text] [Related]
29. [131-I-MIBG--pharmacokinetics and dosimetry].
Blottner A; Bratouss A; Ertl S; Wollny P
Radiobiol Radiother (Berl); 1988; 29(2):202-5. PubMed ID: 3399657
[No Abstract] [Full Text] [Related]
30. Reduction of intratumoral pH by the mitochondrial inhibitor m-iodobenzylguanidine and moderate hyperglycemia.
Kuin A; Smets L; Volk T; Paans A; Adams G; Atema A; Jähde E; Maas A; Rajewsky MF; Visser G
Cancer Res; 1994 Jul; 54(14):3785-92. PubMed ID: 8033098
[TBL] [Abstract][Full Text] [Related]
31. Sympathomimetic effects of MIBG: comparison with tyramine.
Graefe KH; Bossle F; Wölfel R; Burger A; Souladaki M; Bier D; Dutschka K; Farahati J; Bönisch H
J Nucl Med; 1999 Aug; 40(8):1342-51. PubMed ID: 10450687
[TBL] [Abstract][Full Text] [Related]
32. Meta-iodobenzylguanidine and analogues: chemistry and biology.
Vaidyanathan G
Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):351-68. PubMed ID: 19088690
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic imaging in patients with paragangliomas. Computed tomography, magnetic resonance and MIBG scintigraphy comparison.
Maurea S; Cuocolo A; Reynolds JC; Neumann RD; Salvatore M
Q J Nucl Med; 1996 Dec; 40(4):365-71. PubMed ID: 9050342
[TBL] [Abstract][Full Text] [Related]
34. Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model.
Seo Y; Gustafson WC; Dannoon SF; Nekritz EA; Lee CL; Murphy ST; VanBrocklin HF; Hernandez-Pampaloni M; Haas-Kogan DA; Weiss WA; Matthay KK
Mol Imaging Biol; 2012 Dec; 14(6):735-42. PubMed ID: 22382618
[TBL] [Abstract][Full Text] [Related]
35. Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: evidence for uptake-one.
Jaques S; Tobes MC; Sisson JC
Cancer Res; 1987 Aug; 47(15):3920-8. PubMed ID: 3607739
[TBL] [Abstract][Full Text] [Related]
36. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy.
Shulkin BL; Hutchinson RJ; Castle VP; Yanik GA; Shapiro B; Sisson JC
Radiology; 1996 Jun; 199(3):743-50. PubMed ID: 8637999
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic use of I-131-MIBG in nude mice hosting human neuroblastoma xenografts.
Senekowitsch R; Laubenbacher C; Möllenstädt S; Kriegel H; Pabst HW
Strahlenther Onkol; 1989 Jul; 165(7):566-8. PubMed ID: 2749502
[No Abstract] [Full Text] [Related]
38. Evaluation of phenylpiperazines as targeting agents for neuroblastoma.
Babich JW; Graham WA; Fischman AJ
Br J Cancer; 1996 Sep; 74(6):917-24. PubMed ID: 8826858
[TBL] [Abstract][Full Text] [Related]
39. Effect of adrenergic receptor ligands on metaiodobenzylguanidine uptake and storage in neuroblastoma cells.
Babich JW; Graham W; Fischman AJ
Eur J Nucl Med; 1997 May; 24(5):538-43. PubMed ID: 9142735
[TBL] [Abstract][Full Text] [Related]
40. Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG.
Zhang H; Huang R; Cheung NK; Guo H; Zanzonico PB; Thaler HT; Lewis JS; Blasberg RG
Clin Cancer Res; 2014 Apr; 20(8):2182-91. PubMed ID: 24573553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
